• Genmab maintained 2026 revenue guidance of USD 4.33 billion to USD 4.53 billion, implying 19% growth at the midpoint.
• Adjusted operating profit is forecast at USD 1.07 billion to USD 1.39 billion.
• Adjusted operating expenses are projected at USD 2.81 billion to USD 2.95 billion, reflecting accelerated late-stage development and launch preparations.
• EPKINLY growth and continued momentum across the royalty portfolio underpin the revenue outlook.
• Investment focuses on petosemtamab and Rina-S, with multiple potential launches expected in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genmab A/S published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.